emperor-reduced-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Reduced Phase III trial in adults with chronic heart failure with reduced ejection fraction
Search
Retinal health: All eyes on vision loss
Discover how we want to prevent vision loss caused by diabetic retinopathy and other retinal diseases
Practical Advice
Practical advice for people with type 2 diabetes (T2D) at risk of heart disease
It’s Your Heart. Protect It. The Podcast.
In season 2, we hear from a range of experts to explore further how the interconnected systems call for collaboration and approach to care.
Dan
People with Type 2 diabetes (T2D) have an increased risk of heart disease
Reinhold
People with type 2 diabetes have an increased risk of heart disease and this can have a profound impact on their everyday lives
Elke
People with Type 2 diabetes (T2D) have an increased risk of heart disease.
BI_PharmAccess_launch_digital_healthcare_program
Boehringer Ingelheim and PharmAccess launch a new mobile support program „Tiba Yako“ to empower patients to become more aware, access care and take charge of their disease management
emperor-reduced-chmp-positive-opinion
CHMP issues positive opinion for the treatment of adults with heart failure with reduced ejection fraction
reduced-heart-failure-treatment-approval-europe
European approval for treatment of adults with heart failure with reduced ejection fraction
Liu
Hear Liu share his experience of being diagnosed with type 2 diabetes and heart disease on the same day and the impact this simultaneous diagnosis has had on his life as he knew it.
Isabel
In this video, Isabel shares how watching her children and grandchildren grow up inspires her to take the necessary steps to manage her life with type 2 diabetes and heart disease.
Positive results Diabetic Macular Ischemia treatment
HORNBILL Phase I/II study shows positive results for potentially first ever Diabetic Macular Ischemia treatment
SENVELGO Best New Product Companion Animals award
SENVELGO won the 2023 Animal Health Best New Product for Companion Animals award
A Unique Bond: a brotherhood like no other
After being diagnosed with diabetes, Eric’s unique bonds with Peetey and Jake meant they could run miles across the Idaho wilderness.
New treatment for chronic kidney disease approved in the EU
The European Commission (EC) has approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease
Clinical-phase2-trials-NASH-and-obesity
Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
SENVELGO®
For the treatment of feline diabetes mellitus
DCRI-collaboration-empact-mi
Collaboration with Duke Clinical Research Institute on EMPACT-MI trial, which will assess outcomes in people who have had a myocardial infarction
discontinuation-bi-1467335-diabetic-retinopathy
The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced
Phase II trial results in people living with obesity or overweight
Phase II trial with BI 456906 met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardio-renal-metabolic focus areas
Tackling NCDs through innovation AND collaboration
Non-communicable diseases are a significant medical, humanitarian and socio-economic issue. Rapid innovation and holistic approaches help us tackle them
Eyes on Retina. The Podcast
Hear from experts and people living with retinal diseases such as wet age-related macular degeneration (AMD), stargardt disease and diabetic retinopathy.